University of Miami
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Miami sits in the top decile of US sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count).
University of Miami: 721 sponsored US clinical trials, 145 recruiting.
University of Miami sponsors 721 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 430 completed. 79 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 10 trials.
Top-decile sponsor footprint
University of Miami ranks in the top decile of sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
430 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
721 total, page 14 of 15
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
NCT00364689
A Waitlist-Controlled Trial of the Unified Protocol for the Treatment of Emotional Disorders in Adolescents
NCT00628888
Buprenorphine HIV Care Integration Project
NCT00348868
Albumin in Acute Ischemic Stroke Trial
NCT00235495
Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer
NCT02003482
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00448838
Optimizing Pharmacotherapy for Bipolar Alcoholics
NCT00302133
Juvenile Detention to Community Life
NCT01910324
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
NCT00449163
Valproate Efficacy in Cocaine-Bipolar Comorbidity
NCT00240110
A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
NCT00754247
Safety Study to Evaluate the Effect of Lowering Body Temperature During Cochlear Implantation
NCT00375882
HealthSpark 2: Improving Asthma Care for Preschool Children
NCT00304304
Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo
NCT01042665
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
NCT00453102
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
NCT01172418
The Early History of Universal Screening for Metabolic Disorders
NCT00309400
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
NCT01046955
Ahmed Versus Baerveldt Comparison Study
NCT00376363
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
NCT00232479
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
NCT00276861
Family Workshops for Bipolar Disorder
NCT00296283
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00305786
Effects of Leptin Replacement in Children
NCT00659828
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
NCT00449137
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
NCT00448682
Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease
NCT00222378
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
NCT00108485
Myfortic vs. Cellcept in Kidney Transplant Recipients
NCT00533624
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
NCT00448760
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
NCT00183248
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
NCT00344227
Brief Strategic Family Therapy for Adolescent Drug Abusers
NCT00095303
Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children
NCT00260806
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
NCT00373659
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
NCT00290693
The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
NCT00530101
Family-Based Juvenile Drug Court Services
NCT01668303
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
NCT00450372
Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
NCT00450723
HealthSpark: Health Access for Children in Federally-Subsidized Child Care
NCT00339027
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
NCT00077051
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
NCT00450801
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
NCT00450736
Emotional Disclosure in HIV
NCT00067704
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
NCT00448552
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
NCT00449020
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
NCT00076050
Study of the Effects of the Pulsed-dye Laser at 585nm and 595nm to Treat Post-operative Scars on Suture-removal Day
NCT00482144
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
NCT00453336
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 86 |
| Phase 3 | 18 |
| Phase 4 | 61 |
Therapeutic Areas
What is open in the University of Miami pipeline
145 recruiting of 721 indexed (20% open); 430 completed (60%).
Phase mix: 79 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Miami: open-pipeline peers nationwide
Peers matched on 721 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 721 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
Sponsors near 20% open enrollment (± trial volume)
- University of California, Irvine · 20% recruiting · 368 trials
- Endeavor Health · 20% recruiting · 94 trials
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
Related
What to do with this University of Miami page
721 registered trials is a research-attention snapshot, not an endorsement of University of Miami or any single study.
- 145 of University of Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Miami pipeline card: 721 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.